drugset / Trial / NCT03067727

A Randomised Trial Investigating the Efficacy and Safety of a Vaginal Insert in Pregnant Women at Term

NCT03067727

Phase 3 Completed 114 enrolled Ferring Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

To demonstrate the efficacy of dinoprostone vaginal insert (DVI) for cervical ripening success (either bishop score (BS) ≥7 or vaginal delivery) within 12 hours of vaginal insert administration

Timeline

Start
2017-04-03
Primary completion
2018-08-30
Completion
2018-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Dinoprostone Other / unclassified 10 mg Other

Indications